Beth Bronner

Biography

 Beth Bronner, age 64, was elected to the Board of the Company.  Ms. Bronner is Chairperson of the Compensation Committee.  Ms. Bronner has been a Managing Director at Mistral Equity Partners, a private equity firm that specializes in the consumer and food sector, since 2006.  Ms. Bronner is a recognized senior business leader with an outstanding track record delivering strong, profitable revenue and market share growth for marquee brands including: Jim Beam, Revlon, Nabisco, AT&T, Citibank, Haagen-Dazs and Sunbeam. At Revlon, she was President of Revlon Professional, North America.  At Sunbeam, she was President of the Health Division.  At AT&T, she was Vice-President, Consumer Market/Business Markets, and at Citibank, she was Senior Vice President & Chief Marketing Officer of the Consumer/Retail business.  Ms. Bronner also served as Global Chief Marketing Officer of Beam Spirits and Wine. She has demonstrated success in change management, business turnaround, organization restructuring, and high-performance team building.  Ms. Bronner’s proven ability to build brands is the result of strong consumer insights, strategic integrated marketing and superior in market execution.  Ms. Bronner is a former member of the Board of Directors of Jamba, Inc. (June 2009 – September 2012) (JMBA/NASDAQ), Assurant, Inc. (February 1994 – May 2011) (AIZ/NYSE) and Hain Celestial Group, Inc. (January 1993 – November 2010) (HAIN/NASDAQ).  Ms. Bronner also chaired the Compensation Committees for Assurant, Inc. and Hain Celestial Group, Inc. She is a member of The Committee of 200 International Women’s Forum and The Chicago Network.  She currently serves on the boards of several not-for-profit organizations including the President’s Advisory Council of Vassar College.  She is a former board member of The Cradle Foundation, The University of Chicago Laboratory School, The New School, and the Women’s Board of the Museum of Contemporary Art. Ms. Bronner received a B.A. from Vassar College and an M.B.A. from The University of Chicago. We believe that Ms. Bronner’s extensive experience as a senior executive and private equity investor and service on the boards of several multi-billion dollar companies allow Ms. Bronner to make a valuable contribution as one of our directors.

Research Interest

 Pharmaceutics